AstraZeneca PLC (ETR:ZEG)
Germany · Delayed Price · Currency is EUR | Market Cap | 227.76B |
| Revenue (ttm) | 48.11B |
| Net Income (ttm) | 7.06B |
| Shares Out | n/a |
| EPS (ttm) | 4.52 |
| PE Ratio | 32.25 |
| Forward PE | 17.51 |
| Dividend | 2.91 (1.99%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 12,369 |
| Average Volume | 18,477 |
| Open | 146.85 |
| Previous Close | 148.70 |
| Day's Range | 146.55 - 148.25 |
| 52-Week Range | 111.00 - 149.50 |
| Beta | 0.17 |
| RSI | 66.77 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
AstraZeneca To Invest $4.5 Bln In Virginia Facility, Create 3,600 Jobs
(RTTNews) - AstraZeneca Plc. (AZN, AZN.L, ZEG.DE,AZN.ST) announced a $4.5 billion investment in a new advanced manufacturing facility at Rivanna Futures in Albemarle County, Virginia—an increase of $5...
AstraZeneca (AZN) Boosts U.S. Investment with $4.5B Virginia Facility
AstraZeneca (AZN) Boosts U.S. Investment with $4.5B Virginia Facility
AstraZeneca (AZN) Invests $4.5B in New Virginia Facility to Boost Medicine Production
AstraZeneca (AZN) Invests $4.5B in New Virginia Facility to Boost Medicine Production
Turbine Partners With AstraZeneca To Accelerate AI-Driven ADC Discovery
(RTTNews) - AstraZeneca (AZN), Thursday announced a collaboration with Turbine, a biotechnology company specializing in AI-powered virtual biological experiments, to advance the discovery of antibody-...
AstraZeneca eyes $500M additional investment in new Virginia plant
AstraZeneca (AZN) stock is in focus as the company invests $4.5B in a new Virginia plant to boost U.S. manufacturing, $500M more than its initial plan. Read more here.
AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump
AstraZeneca broke ground on a new plant in Virginia on Thursday and said it would spend $4.5 billion on the facility as drugmakers look to respond to President Donald Trump's call for more medicines t...
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces that it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manu...
A Look Into AstraZeneca Inc's Price Over Earnings
In the current session, the stock is trading at $86.19, after a 0.94% increase. Over the past month, AstraZeneca Inc. (NASDAQ: AZN) stock increased by 6.27% , and in the past year, by 11.42% . With p...
Collaboration Between Turbine and AstraZeneca (AZN) Enhances ADC Discovery
Collaboration Between Turbine and AstraZeneca (AZN) Enhances ADC Discovery
AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Drugs
AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Drugs
Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery
LONDON, UK and BUDAPEST, HUNGARY , Oct. 9, 2025 /PRNewswire/ -- Turbine, a leading company specializing in virtualizing biological experiments with AI, today announced a collaboration with AstraZeneca...
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.
AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial
AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial
AZN: Baxdrostat Shows Promising Results in Phase III Trial
AZN: Baxdrostat Shows Promising Results in Phase III Trial
AstraZeneca succeeds in late-stage trial for blood pressure therapy
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in a...
AZN : Baxdrostat Meets Primary Endpoint In Phase III Trial For Treatment-Resistant Hypertension
(RTTNews) - AstraZeneca (AZN, AZN.L,ZEG.DE,AZN.ST) announced that baxdrostat met the primary endpoint in the Bax24 Phase III trial, demonstrating a statistically significant and clinically meaningful ...
AstraZeneca's Baxdrostat meets main goal in high blood pressure study
AstraZeneca said on Tuesday its drug Baxdrostat met the main goal in a late-stage study in patients with treatment-resistant high blood pressure, or hypertension.
AstraZeneca (AZN) Signs $555 Million AI Agreement with Algen to Develop Therapies
AstraZeneca (AZN) Signs $555 Million AI Agreement with Algen to Develop Therapies
AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treatment Study
AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treatment Study
AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases
Algen Biotechnologies , a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NA...
AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study
AstraZeneca & Daiichi Sankyo's Datroway shows improved survival in late-stage triple-negative breast cancer trial. Read more here.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies
Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a dea...
Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca.